JP2016536361A - Ｃｄ３３抗体及び脱メチル剤を含む医薬配合物 - Google Patents

Ｃｄ３３抗体及び脱メチル剤を含む医薬配合物 Download PDF

Info

Publication number
JP2016536361A
JP2016536361A JP2016551017A JP2016551017A JP2016536361A JP 2016536361 A JP2016536361 A JP 2016536361A JP 2016551017 A JP2016551017 A JP 2016551017A JP 2016551017 A JP2016551017 A JP 2016551017A JP 2016536361 A JP2016536361 A JP 2016536361A
Authority
JP
Japan
Prior art keywords
seq
antibody
administration
cancer
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016551017A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016536361A5 (enExample
Inventor
カール−ハインツ ハイデル
カール−ハインツ ハイデル
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング, ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2016536361A publication Critical patent/JP2016536361A/ja
Publication of JP2016536361A5 publication Critical patent/JP2016536361A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2016551017A 2013-11-06 2014-11-03 Ｃｄ３３抗体及び脱メチル剤を含む医薬配合物 Pending JP2016536361A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13191839.3 2013-11-06
EP13191839 2013-11-06
PCT/EP2014/073612 WO2015067570A2 (en) 2013-11-06 2014-11-03 Pharmaceutical combinations comprising cd33 antibodies and de-methylating agents

Publications (2)

Publication Number Publication Date
JP2016536361A true JP2016536361A (ja) 2016-11-24
JP2016536361A5 JP2016536361A5 (enExample) 2017-12-14

Family

ID=49518850

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016551017A Pending JP2016536361A (ja) 2013-11-06 2014-11-03 Ｃｄ３３抗体及び脱メチル剤を含む医薬配合物

Country Status (4)

Country Link
US (2) US20150125447A1 (enExample)
EP (1) EP3066125A2 (enExample)
JP (1) JP2016536361A (enExample)
WO (1) WO2015067570A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
JP6707531B2 (ja) 2014-09-09 2020-06-10 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体による併用療法
TWI721959B (zh) 2014-12-04 2021-03-21 美商健生生物科技公司 治療急性骨髓性白血病之抗ｃｄ３８抗體
MX389805B (es) 2015-05-20 2025-03-11 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
NZ777133A (en) 2015-06-22 2025-05-02 Janssen Biotech Inc Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US20160376373A1 (en) * 2015-06-24 2016-12-29 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
HK1248115A1 (zh) * 2015-07-16 2018-10-12 Bioxcel Therapeutics, Inc. 一种使用免疫调节治疗癌症的新颖方法
SMT202100192T1 (it) 2015-11-03 2021-05-07 Janssen Biotech Inc Formulazioni sottocutanee di anticorpi anti-cd38 e loro usi.
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
WO2017160954A1 (en) 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
EP3463463A4 (en) 2016-06-03 2020-01-15 Seattle Genetics, Inc. Combination of cd33 antibody drug conjugates with chemotherapeutic agents
WO2017214433A1 (en) 2016-06-09 2017-12-14 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with flt3 inhibitors
AU2018359527A1 (en) 2017-10-31 2020-05-07 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
US11963683B2 (en) 2020-10-02 2024-04-23 Cilag Gmbh International Method for operating tiered operation modes in a surgical system
US12213801B2 (en) 2020-10-02 2025-02-04 Cilag Gmbh International Surgical visualization and particle trend analysis system
US11830602B2 (en) 2020-10-02 2023-11-28 Cilag Gmbh International Surgical hub having variable interconnectivity capabilities
US11992372B2 (en) 2020-10-02 2024-05-28 Cilag Gmbh International Cooperative surgical displays
US12064293B2 (en) 2020-10-02 2024-08-20 Cilag Gmbh International Field programmable surgical visualization system
US11672534B2 (en) 2020-10-02 2023-06-13 Cilag Gmbh International Communication capability of a smart stapler
US11877897B2 (en) 2020-10-02 2024-01-23 Cilag Gmbh International Situational awareness of instruments location and individualization of users to control displays
US12472032B2 (en) 2020-10-02 2025-11-18 Cilag Gmbh International Monitoring of user visual gaze to control which display system displays the primary information
US12016566B2 (en) 2020-10-02 2024-06-25 Cilag Gmbh International Surgical instrument with adaptive function controls
US11748924B2 (en) 2020-10-02 2023-09-05 Cilag Gmbh International Tiered system display control based on capacity and user operation
US12484897B2 (en) 2020-10-02 2025-12-02 Cilag Gmbh International Surgical instrument with adaptive configuration control
CN116948029A (zh) 2022-04-20 2023-10-27 南京融捷康生物科技有限公司 一种包含IgG类Fc区变体的抗体及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012045752A1 (en) * 2010-10-04 2012-04-12 Boehringer Ingelheim International Gmbh Cd33 binding agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040152632A1 (en) * 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
WO2006050075A2 (en) * 2004-10-29 2006-05-11 Regents Of The University Of California Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012045752A1 (en) * 2010-10-04 2012-04-12 Boehringer Ingelheim International Gmbh Cd33 binding agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 122, JPN6018032793, October 2013 (2013-10-01), pages 3959, ISSN: 0004001253 *
MABS, vol. 2, no. 4, JPN6018032792, 2010, pages 440 - 448, ISSN: 0004001252 *

Also Published As

Publication number Publication date
US20150125447A1 (en) 2015-05-07
WO2015067570A2 (en) 2015-05-14
US20180064811A1 (en) 2018-03-08
EP3066125A2 (en) 2016-09-14
WO2015067570A3 (en) 2015-07-16

Similar Documents

Publication Publication Date Title
JP2016536361A (ja) Ｃｄ３３抗体及び脱メチル剤を含む医薬配合物
US12121579B2 (en) Antibodies specific to human t-cell immunoglobulin and ITIM domain (TIGIT)
JP7286543B2 (ja) Ｃｅａを標的にする多重特異性結合タンパク質
US12384847B2 (en) Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen
AU2018220734B2 (en) Proteins binding CD33, NKG2D and CD16
US20210221894A1 (en) Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams
US20140093499A1 (en) Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf agents
JP2023030174A (ja) Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質
US20190375838A1 (en) Proteins binding bcma, nkg2d and cd16
WO2019055677A1 (en) NKG2D, CD16, AND LIQUID-LIKE MOLECULE-1-LIKE PROTEINS (CLL-1)
US20200024353A1 (en) Proteins binding psma, nkg2d and cd16
EP3630169A1 (en) A protein binding nkg2d, cd16 and a tumor-associated antigen
BR112021002276A2 (pt) proteínas de ligação a nkg2d, cd16 e um antígeno associado ao tumor
US20140093498A1 (en) Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents
RU2802812C2 (ru) Лечебный подход, предназначенный для лечения комбинацией антитела к CD19 и венетоклакса
RU2820629C2 (ru) Полиспецифические связывающие белки, нацеленные на nkg2d, cd16 и trop2
WO2023051674A1 (zh) 联合治疗血液肿瘤的抗cd47抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180827

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190322